HRSA-21-053: Autism Field-Initiated Innovative Research Studies Program (Autism-FIRST)
Closed
This grant is closed. Who won this program's grants before is below, and similar open grants are at the end of the page. It is in our archive of Health Resources and Services Administration notices from 2021.
Health Resources and Services Administration offered grants to the applicants described in the notice. It expected to make about 2 awards worth $600,000 in total. Applications closed on April 15, 2021.
From the official notice on Grants.gov, last changed January 15, 2021. Checked November 7, 2026.
- Total funding$600,000
- Expected awards2
- Cost sharingNot required
- Funding typeGrant
Key dates
| Posted | January 15, 2021 |
|---|---|
| Deadline | April 15, 2021 |
| Archived by Grants.gov | June 14, 2021 |
Who can apply
This opportunity was open to the applicants described in the notice.
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
Eligible applicants include any domestic public or private entity, including research centers or networks. Domestic faith-based and community-based organizations, tribes, and tribal organizations are eligible to apply.
Is this a realistic fit?
- No cost sharing or match is required.
What the grant funds
Bureau (MCHB)’s Office of Epidemiology and Research is accepting applications for the fiscal year (FY) 2021 Autism Field-Initiated Innovative Research Studies (Autism-FIRST) Program. The purpose of this program is to support empirical research that advances the evidence base on interventions designed to improve the health of children, adolescents, and young adults with autism spectrum disorders and other developmental disabilities (ASD/DD) across the lifespan. Because racial and ethnic disparities exist in the early screening and diagnosis of ASD/DD, the Autism-FIRST Program has a special focus on addressing the needs of underserved populations, such as low-income, racial/ethnic minorities, individuals living in rural areas and, in the case of ASD/DD populations, girls and young women, who are often under identified with regard to ASD, particularly at the higher functioning end.1 The Autism-FIRST program supports research studies that address critical issues surrounding the health and well-being of underserved children, adolescents, and young adults with ASD/DD up to the age of 26, and their families, recognizing that the first 25 years of life help lay the foundation for health and well-being across the lifespan. A focus on underserved populations is consistent with HRSA’s mission as an agency that promotes access to equitable and coordinated health and health care delivery services. A focus on children, adolescents, and young adults up to the age of 26 is consistent with the mission of the Maternal and Child Health Bureau (MCHB) and the populations it serves. The Autism-FIRST’s program’s goals and objectives are to: • Generate new evidence to address the needs of underserved ASD/DD populations for whom there is limited evidence of the effectiveness of interventions, and limited access to screening, diagnosis, and treatment for ASD/DD; • Contribute to the broad public health impact to improve health and service delivery services through studies that are generalizable and replicable for underserved ASD/DD populations; and • Conduct and disseminate findings from applied and/or translational research on critical and emerging ASD/DD issues using a research design focused on collection of primary data among underserved populations, with a special focus on underserved populations and children, adolescents, and young adults up to the age of 26.
Who has won Autism Collaboration, Accountability, Research, Education, and Support grants before
From fiscal 2021 to 2025, Autism Collaboration, Accountability, Research, Education, and Support (93.877) awarded $103 million across 105 grant awards, an average of $981,155 per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| University of California, Los Angeles | California | 6 | $8.5 million |
| The Children's Hospital of Philadelphia | Pennsylvania | 4 | $3.5 million |
| University of Wisconsin System | Wisconsin | 3 | $3.4 million |
| University of California, Davis | California | 3 | $2.8 million |
| The Regents of the University of Colorado | Colorado | 2 | $2.2 million |
Applying now
This notice no longer takes applications. Agencies often post the same opportunity again under a new number, so check the program's notices on Grants.gov and the similar open grants below.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is HRSA-21-053 still open?
No. It closed on April 15, 2021.
Who can apply for Autism Field-Initiated Innovative Research Studies Program (Autism-FIRST)?
Health Resources and Services Administration accepted applications from the applicants described in the notice. The notice adds further conditions, so read its eligibility section.
What is the deadline for Autism Field-Initiated Innovative Research Studies Program (Autism-FIRST)?
Closed April 15, 2021. Applications are no longer accepted; the program's newer notices are on this page when there are any.
How much funding is available?
About $600,000 in total across about 2 awards.
Who has won Autism Collaboration, Accountability, Research, Education, and Support grants before?
The largest recipients over five fiscal years were University of California, Los Angeles, The Children's Hospital of Philadelphia, University of Wisconsin System. The program made 105 awards worth $103 million in that time.
Similar open grants
- Single Source for the Continuation of the Caring for OutPatiEnts after Acute Kidney Injury (COPE-AKI) Scientific and Data Research Center (U01 Clinical Trial Required)
- Single Source for the Continuation of the Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Center (Collaborative U01 Clinical Trial Not Allowed)
- Data Coordinating Center for the Aging and Alzheimer’s Disease Mouse Brain Atlas (AD-MBA) (U24 Clinical Trial Not Allowed)
- Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)
- Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)
- Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)